These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31673100)

  • 1. GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome.
    Seppa K; Toots M; Reimets R; Jagomäe T; Koppel T; Pallase M; Hasselholt S; Krogsbæk Mikkelsen M; Randel Nyengaard J; Vasar E; Terasmaa A; Plaas M
    Sci Rep; 2019 Oct; 9(1):15742. PubMed ID: 31673100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype.
    Jagomäe T; Seppa K; Reimets R; Pastak M; Plaas M; Hickey MA; Kukker KG; Moons L; De Groef L; Vasar E; Kaasik A; Terasmaa A; Plaas M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome.
    Toots M; Seppa K; Jagomäe T; Koppel T; Pallase M; Heinla I; Terasmaa A; Plaas M; Vasar E
    Sci Rep; 2018 Jul; 8(1):10183. PubMed ID: 29976929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model.
    Seppa K; Jagomäe T; Kukker KG; Reimets R; Pastak M; Vasar E; Terasmaa A; Plaas M
    Sci Rep; 2021 Jan; 11(1):2275. PubMed ID: 33500541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Expression of RAAS Key Receptors,
    Punapart M; Seppa K; Jagomäe T; Liiv M; Reimets R; Kirillov S; Kaasik A; Moons L; De Groef L; Terasmaa A; Vasar E; Plaas M
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome.
    Kondo M; Tanabe K; Amo-Shiinoki K; Hatanaka M; Morii T; Takahashi H; Seino S; Yamada Y; Tanizawa Y
    Diabetologia; 2018 Oct; 61(10):2189-2201. PubMed ID: 30054673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration.
    Plaas M; Seppa K; Reimets R; Jagomäe T; Toots M; Koppel T; Vallisoo T; Nigul M; Heinla I; Meier R; Kaasik A; Piirsoo A; Hickey MA; Terasmaa A; Vasar E
    Sci Rep; 2017 Aug; 7(1):10220. PubMed ID: 28860598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of GLP-1 Agonist Therapy in Autosomal Dominant WFS1-Related Disorder: A Case Report.
    Scully KJ; Wolfsdorf JI
    Horm Res Paediatr; 2020; 93(6):409-414. PubMed ID: 33075784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deep phenotyping study in mouse and iPSC models to understand the role of oligodendroglia in optic neuropathy in Wolfram syndrome.
    Ahuja K; Vandenabeele M; Nami F; Lefevere E; Van Hoecke J; Bergmans S; Claes M; Vervliet T; Neyrinck K; Burg T; De Herdt D; Bhaskar P; Zhu Y; Looser ZJ; Loncke J; Gsell W; Plaas M; Agostinis P; Swinnen JV; Van Den Bosch L; Bultynck G; Saab AS; Wolfs E; Chai YC; Himmelreich U; Verfaillie C; Moons L; De Groef L
    Acta Neuropathol Commun; 2024 Aug; 12(1):140. PubMed ID: 39198924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
    Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
    Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Stress Alters Hippocampal Renin-Angiotensin-Aldosterone System Component Expression in an Aged Rat Model of Wolfram Syndrome.
    Punapart M; Reimets R; Seppa K; Kirillov S; Gaur N; Eskla KL; Jagomäe T; Vasar E; Plaas M
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.
    Shu X; Zhang Y; Li M; Huang X; Yang Y; Zeng J; Zhao Y; Wang X; Zhang W; Ying Y
    Neuropharmacology; 2019 Jul; 153():1-12. PubMed ID: 31015047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of Liraglutide on diabetic retinal neurodegeneration via inhibiting oxidative stress and endoplasmic reticulum stress.
    Liu J; Wei L; Wang Z; Song S; Lin Z; Zhu J; Ren X; Kong L
    Neurochem Int; 2020 Feb; 133():104624. PubMed ID: 31794832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel heterozygous mutation of the WFS1 gene leading to constitutive endoplasmic reticulum stress is the cause of Wolfram syndrome.
    Morikawa S; Tajima T; Nakamura A; Ishizu K; Ariga T
    Pediatr Diabetes; 2017 Dec; 18(8):934-941. PubMed ID: 28271591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wolfram syndrome: new pathophysiological insights and therapeutic strategies.
    Mishra R; Chen BS; Richa P; Yu-Wai-Man P
    Ther Adv Rare Dis; 2021; 2():26330040211039518. PubMed ID: 37181110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome.
    Nguyen LD; Fischer TT; Abreu D; Arroyo A; Urano F; Ehrlich BE
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17389-17398. PubMed ID: 32632005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
    Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.
    Gorgogietas V; Rajaei B; Heeyoung C; Santacreu BJ; Marín-Cañas S; Salpea P; Sawatani T; Musuaya A; Arroyo MN; Moreno-Castro C; Benabdallah K; Demarez C; Toivonen S; Cosentino C; Pachera N; Lytrivi M; Cai Y; Carnel L; Brown C; Urano F; Marchetti P; Gilon P; Eizirik DL; Cnop M; Igoillo-Esteve M
    Diabetologia; 2023 Jul; 66(7):1306-1321. PubMed ID: 36995380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome.
    Jagomäe T; Gaur N; Seppa K; Reimets R; Pastak M; Plaas M; Kaasik A; Vasar E; Plaas M
    Front Endocrinol (Lausanne); 2023; 14():1234925. PubMed ID: 37900147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.
    Filchenko I; Simanenkova A; Chefu S; Kolpakova M; Vlasov T
    Diab Vasc Dis Res; 2018 Nov; 15(6):567-570. PubMed ID: 30024276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.